QUINCE THERAPEUTICS INC(NASDAQ:QNCX) stock News

QNCX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

7 days ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

22 days ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference

a year ago - By: BusinessInsider

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024

a month ago - By: Benzinga - Mentions: LIXT ATRA PPBT MODV ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

a month ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

a month ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

a year ago - By: InvestorPlace

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024

a year ago - By: InvestorPlace

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024

a month ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

2 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

2 months ago - By: Benzinga - Mentions: UMAC SDM NITO HUN ...

Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

2 months ago - By: Yahoo Finance - Mentions: SRPT PLTR FTNT JPM

Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks

3 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Present at Citizens Life Sciences Conference

4 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

4 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

5 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

5 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

5 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

6 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

6 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

6 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

8 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

8 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

8 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

9 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Participate at Upcoming Investor Conferences

11 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

a year ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

a year ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

a year ago - By: Quince Therapeutics, Inc.

QUINCE THERAPEUTICS INC (QNCX) Stock News

QNCX Latest News, Press Relases and Analysis

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024

12 Health Care Stocks Moving In Wednesday's After-Market Session

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks

Quince Therapeutics to Present at Citizens Life Sciences Conference

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Quince Therapeutics to Participate at Upcoming Investor Conferences

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System